Erratum: “Baseline characteristics of idiopathic pulmonary fibrosis: Analysis from the Australian Idiopathic Pulmonary Fibrosis Registry.” Helen E. Jo, Ian Glaspole, Christopher Grainge, Nicole Goh, Peter M.A. Hopkins, Yuben Moodley, Paul N. Reynolds, Sally Chapman, E. Haydn Walters, Christopher Zappala, Heather Allan, Gregory J. Keir, Andrew Hayen, Wendy A. Cooper, Annabelle M. Mahar, Samantha Ellis, Sacha Macansh and Tamera J. Corte (European Respiratory Journal (2017) 49 (1601592) DOI: 10.1183/13993003.01592-2016);Baseline characteristics of idiopathic pulmonary fibrosis: Analysis from the Australian Idiopathic Pulmonary Fibrosis Registry

European Respiratory Journal

Volumn 49, Issue 2, 2017, Pages

  Jo, Helen E ^a,b   Glaspole, Ian ^c,d   Grainge, Christopher ^e   Goh, Nicole ^c,f   Hopkins, Peter M A ^g   Moodley, Yuben ^h   Reynolds, Paul N ⁱ   Chapman, Sally ⁱ   Walters, E Haydn ^j   Zappala, Christopher ^k   Allan, Heather ^l   Keir, Gregory J ^m   Hayen, Andrew ^a   Cooper, Wendy A ^a   Mahar, Annabelle M ^c   Ellis, Samantha ^c   Macansh, Sacha ^l   Corte, Tamera J ^a,b  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^b University of Sydney   (Australia)

^c ALFRED HOSPITAL   (Australia)

^d MONASH UNIVERSITY   (Australia)

^e JOHN HUNTER HOSPITAL   (Australia)

^f AUSTIN HOSPITAL   (Australia)

^g UNIVERSITY OF QUEENSLAND   (Australia)

^h FIONA STANLEY HOSPITAL   (Australia)

ⁱ ROYAL ADELAIDE HOSPITAL   (Australia)

^j UNIVERSITY OF TASMANIA   (Australia)

^k ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^l Lung Foundation Australia   (Australia)

^m PRINCESS ALEXANDRA HOSPITAL   (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ANTIFIBROTIC AGENT; AZATHIOPRINE; CARBON MONOXIDE; PREDNISONE;

AGE; AGED; ARTICLE; AUSTRALIA; COMORBIDITY; CONTROLLED STUDY; DEMOGRAPHY; DISEASE COURSE; DISEASE REGISTRY; DISEASE SEVERITY; FEMALE; FIBROSING ALVEOLITIS; FOLLOW UP; FORCED VITAL CAPACITY; HUMAN; LONGITUDINAL STUDY; LUNG DIFFUSION CAPACITY; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; MORTALITY RATE; PATIENT CARE; PREVALENCE; PRIORITY JOURNAL; SURVIVAL; ADULT; AGE DISTRIBUTION; BLOOD; CLINICAL TRIAL; EPIDEMIOLOGY; LUNG; MIDDLE AGED; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; PATHOPHYSIOLOGY; PROSPECTIVE STUDY; REGISTER; SURVIVAL ANALYSIS; VERY ELDERLY; VITAL CAPACITY;

ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; AUSTRALIA; CARBON MONOXIDE; FEMALE; FOLLOW-UP STUDIES; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; LUNG; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROSPECTIVE STUDIES; REGISTRIES; SURVIVAL ANALYSIS; VITAL CAPACITY;

EID: 85029178289     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/13993003.51592-2016     Document Type: Erratum

References (30)

1. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183: 788-824.
2. Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014; 370: 2071-2082.
3. King TE Jr, Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 2014; 370: 2083-2092.
4. Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 2011; 377: 1760-1769.
5. Richeldi L, Costabel U, Selman M, et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med 2011; 365: 1079-1087.
6. Ley B, Collard HR, King TE Jr. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011; 183: 431-440.
7. King TE Jr, Tooze JA, Schwarz MI, et al. Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model. Am J Respir Crit Care Med 2001; 164: 1171-1181.
8. Erbes R, Schaberg T, Loddenkemper R. Lung function tests in patients with idiopathic pulmonary fibrosis. Are they helpful for predicting outcome? Chest 1997; 111: 51-57.
9. Nadrous HF, Pellikka PA, Krowka MJ, et al. Pulmonary hypertension in patients with idiopathic pulmonary fibrosis. Chest 2005; 128: 2393-2399.
10. Nadrous HF, Myers JL, Decker PA, et al. Idiopathic pulmonary fibrosis in patients younger than 50 years. Mayo Clin Proc 2005; 80: 37-40.
11. Manali ED, Stathopoulos GT, Kollintza A, et al. The Medical Research Council chronic dyspnea score predicts the survival of patients with idiopathic pulmonary fibrosis. Respir Med 2008; 102: 586-592.
12. Iwasawa T, Asakura A, Sakai F, et al. Assessment of prognosis of patients with idiopathic pulmonary fibrosis by computer-aided analysis of CT images. J Thorac Imaging 2009; 24: 216-222.
13. Lettieri CJ, Nathan SD, Browning RF, et al. The distance-saturation product predicts mortality in idiopathic pulmonary fibrosis. Respir Med 2006; 100: 1734-1741.
14. Ley B, Bradford WZ, Vittinghoff E, et al. Predictors of mortality poorly predict common measures of disease progression in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2016; 194: 711-718.
15. Ryerson CJ, Corte TJ, Collard HR, et al. A global registry for idiopathic pulmonary fibrosis: the time is now. Eur Respir J 2014; 44: 273-276.
16. Behr J, Kreuter M, Hoeper MM, et al. Management of patients with idiopathic pulmonary fibrosis in clinical practice: the INSIGHTS-IPF registry. Eur Respir J 2015; 46: 186-196.
17. Moodley Y, Goh N, Glaspole I, et al. Australian Idiopathic Pulmonary Fibrosis Registry: vital lessons from a national prospective collaborative project. Respirology 2014; 19: 1088-1091.
18. Ley B, Ryerson CJ, Vittinghoff E, et al. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med 2012; 156: 684-691.
19. Kaunisto J, Kelloniemi K, Sutinen E, et al. Re-evaluation of diagnostic parameters is crucial for obtaining accurate data on idiopathic pulmonary fibrosis. BMC Pulm Med 2015; 15: 92.
20. Ferrara G, Carlson L, Palm A, et al. Idiopathic pulmonary fibrosis in Sweden: report from the first year of activity of the Swedish IPF-Registry. Eur Clin Respir J 2016; 3: 31090.
21. Wells AU, Desai SR, Rubens MB, et al. Idiopathic pulmonary fibrosis: a composite physiologic index derived from disease extent observed by computed tomography. Am J Respir Crit Care Med 2003; 167: 962-969.
22. Raghu G, Rochwerg B, Zhang Y, et al. An official ATS/ERS/JRS/ALAT Clinical Practice Guideline: treatment of idiopathic pulmonary fibrosis. An update of the 2011 Clinical Practice Guideline. Am J Respir Crit Care Med 2015; 192: e3-e19.
23. O'Brien EC, Durheim MT, Gamerman V, et al. Rationale for and design of the Idiopathic Pulmonary Fibrosis-PRospective Outcomes (IPF-PRO) registry. BMJ Open Respir Res 2016; 3: e000108.
24. Hamada K, Nagai S, Tanaka S, et al. Significance of pulmonary arterial pressure and diffusion capacity of the lung as prognosticator in patients with idiopathic pulmonary fibrosis. Chest 2007; 131: 650-656.
25. Mogulkoc N, Brutsche MH, Bishop PW, et al. Pulmonary function in idiopathic pulmonary fibrosis and referral for lung transplantation. Am J Respir Crit Care Med 2001; 164: 103-108.
26. Lynch DA, Godwin JD, Safrin S, et al. High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis. Am J Respir Crit Care Med 2005; 172: 488-493.
27. Shin KM, Lee KS, Chung MP, et al. Prognostic determinants among clinical, thin-section CT, and histopathologic findings for fibrotic idiopathic interstitial pneumonias: tertiary hospital study. Radiology 2008; 249: 328-337.
28. American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med 2000; 161(2 Pt 1): 646-664.
29. Demedts M, Behr J, Buhl R, et al. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 2005; 353: 2229-2242.
30. Idiopathic Pulmonary Fibrosis Clinical Research Network, Raghu G, Anstrom KJ, et al. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med 2012; 366: 1968-1977.